Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER -ALZ 2, a Phase 3 Randomized Trial
TRAILBLAZER-ALZ 2 is a phase 3 study designed to evaluate safety and efficacy of donanemab in individuals with early symptomatic AD with the presence of brain amyloid and tau pathology.
